Biocon Shares Jump 8% After Mylan Launches Rs 3,481 Crore Block Deal

Mumbai, July 14: Biocon share price surged as much as 8% in early trade on Tuesday after Viatris-owned Mylan launched a block deal to sell its entire stake in the biopharmaceutical company, a move that is expected to mark the US drugmaker’s complete exit from Biocon. The stock climbed, putting it on track for its biggest single-day gain in nearly 18 months.  

The proposed transaction involves the sale of up to 9.2 crore shares, representing 5.64% of Biocon’s outstanding equity, and is valued at as much as Rs 3,481 crore. The offer was launched through a block deal with a floor price of Rs 378.50 per share, implying a discount of about 7.9% to Monday’s closing price of Rs 410.95. Citigroup Global Markets India and Jefferies India are acting as joint bookrunners for the transaction. As of writing the stock was up 7.6% at Rs 442. 

Block deals fuel buying interest 

Market participants witnessed heavy trading activity soon after the opening bell, with two large block deals accounting for nearly 9 crore shares, almost matching the quantity Mylan was expected to offload.

Stock rallied after massive block deals in early trade. Source: NSE 

Around 4.4 crore shares changed hands in the first block deal, followed by another transaction involving 4.6 crore shares. While the identity of the buyer was not immediately known, the scale of the transactions suggested that institutional investors stepped in to absorb the stake sale.  

Large block deals are generally executed at a discount to prevailing market prices to facilitate the transfer of sizeable holdings. Although such transactions often create short-term pressure on the stock, successful execution and strong institutional demand are frequently viewed as positive signals by the market. 

Why is Mylan exiting? 

Mylan, a subsidiary of global healthcare company Viatris, held a 5.64% stake in Biocon at the end of FY26. According to reports, the lock-in period on the shares has expired, allowing the company to monetise its investment through a complete exit.  

Mylan acquired the stake earlier this year after Biocon completed the acquisition of the firm’s stake in Biocon Biologics through a combination of cash and a preferential allotment of Biocon shares. As a result, Mylan became a shareholder in Biocon.  

Shareholding pattern in focus 

As of March 31, 2026, promoter Kiran Mazumdar-Shaw owned nearly 30% of Biocon, while Glentec International held around 15%. Mutual funds collectively owned more than 15% of the company, insurance firms held over 6%, and nearly 3.74 lakh retail shareholders together owned around 6%.  

With Mylan’s exit, investors will closely watch the revised shareholding pattern in the coming quarters to identify the institutional investors that have acquired the stake. 

The Biocon stock was up around 7% over the past week and nearly 12% so far in 2026 before Tuesday’s rally. Over the past three years, Biocon has delivered returns of around 66%.  

The positive reaction also suggests investors remain optimistic about Biocon’s core pharmaceuticals and biosimilars businesses, despite near-term changes in its shareholder base. 

What investors should watch 

The successful completion of one of the year’s largest block deals in the pharmaceutical sector is likely to remove a longstanding ownership overhang on Biocon’s stock. 

Going forward, investors will watch for disclosures on the identities of the institutional buyers, any changes in foreign and domestic institutional ownership, and the company’s upcoming quarterly earnings. The market will also monitor whether fresh institutional participation improves liquidity and broadens the shareholder base, potentially supporting the stock over the medium term.  

Source

• https://www.nseindia.com/get-quote/equity/BIOCON/Biocon-Limited